supplied by Biotrend
Formulation: Ig fraction
Reacts in: Sheep
No Available References
- A Close Look at Passive Immunotherapy Newbie, Crenezumab
- Bapineuzumab Phase 3: Target Engagement, But No Benefit
- DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor
- CTAD: Turning the Ship Around Toward Early Trials
- Philadelphia: Can a Shrinking Brain Be Good for You?
- No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
- Clinical Trials of Intravenous Bapineuzumab Halted
- Phase 3 Solanezumab Trials "Fail"—Is There a Silver Lining?
- The Solanezumab Benefit: Oh, So Small, But Probably Real